There are several things that need to happen before the new Alzheimer's drug from Biogen and Eisai gets into the hands of patients. And, unlike with their first Alzheimer's drug, Aduhelm, Eisai is taking the charge on this one — leaving Biogen in a bit of a wait-and-see position.
